Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AZD3293

- PMLiVE

AstraZeneca steps up cancer immunotherapy research

MedImmune unit will study anti-PD1 drug in combination with Advaxis’ cervical cancer vaccine

- PMLiVE

AZ unveils plans for new Cambridge HQ

Construction of its Cambridge Biomedical Campus will start early next year

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

- PMLiVE

AZ sues to block generic saxagliptin from Mylan

Attempt to protect diabetes treatments Onglyza and Kombiglyze XR

- PMLiVE

AZ needs more data on olaparib, says FDA panel

Agency advisers demands more safety information on ovarian cancer drug

AZ expands its mHealth services with new COPD initiative

Partners with Exco InTouch to launch Me&MyCOPD programme

- PMLiVE

ADA: AZ plans to file Onglyza/Forxiga pill by year-end

Diabetes prospects could help justify decision to turn down Pfizer bid

- PMLiVE

AstraZeneca has clearer route to Movantik approval in US

Won't have to carry out cardiovascular outcomes study prior to approval

- PMLiVE

AZ licenses asthma infection drug from Synairgen

Boosts respiratory portfolio with $232m deal

- PMLiVE

AFFiRiS claims a first in Alzheimer’s disease therapy

Says AD04 is first drug to demonstrate disease modification

- PMLiVE

AstraZeneca backs mental health campaign

Pharma company supports Mental Health America

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links